Skip to content
ERNAWErnexa Therapeutics Inc.

Earnings

When Ernexa Therapeutics Inc. reports, what it reported each quarter, and how the stock took the results.

66 quarters. Jun 30, 2010 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

10-K due Mar 9 – 25

No earnings release is on file for this company, so the day is the 10-K’s, projected from its last 8 filings.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 9 – 25

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
—
Revenue, change from a year earlier: Q4 2024 n/m, Q3 2024 +854.9%, Q2 2024 n/m, Q1 2024 n/m
Net income
-$1.50M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q4 2024 · derived$1.00KNo Q4 2023 on file

Latest results

  1. Q3 2026Nov 6, 2026, after the close
    Revenue
    —
    —
    Net income
    -$2.94M
    N/M
    EPS
    -$1.89
    N/M
  2. Q2 2026Aug 6, 2026, after the close
    Revenue
    —
    —
    Net income
    -$4.01M
    N/M
    EPS
    -$3.40
    N/M
  3. Q1 2026May 11, 2026, after the close+85.7%by the close of May 12
    Revenue
    —
    —
    Net income
    -$5.51M
    N/M
    EPS
    -$6.95
    N/M
  4. Q4 2025Mar 13, 2026, after the close+137.0%by the close of Mar 17
    Revenue
    —
    —
    Net income
    -$1.50M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026—Nov 6, 202637 d10-Q——-$1.89—
Q2 2026Jun 30, 2026—Aug 6, 202637 d10-Q——-$3.40—
Q1 2026Mar 31, 2026—May 11, 202641 d10-Q——-$6.95+85.7%
FY 2025
Q4 2025derivedDec 31, 2025—Mar 13, 202672 d10-K———+137.0%
Q3 2025Sep 30, 2025—Nov 7, 202538 d10-Q——-$3.77—
Q2 2025Jun 30, 2025—Aug 13, 202544 d10-Q——-$15.19—
Q1 2025Mar 31, 2025—May 7, 202537 d10-Q——-$57.76—
FY 2024
Q4 2024derivedDec 31, 2024—Mar 12, 202571 d10-K$1.00K———
Q3 2024Sep 30, 2024—Nov 12, 202443 d10-Q$487.00K+854.9%-$73.70—
Q2 2024Jun 30, 2024—Aug 13, 202444 d10-Q$47.00K—-$15.34—
Q1 2024Mar 31, 2024—May 14, 202444 d10-Q$47.00K—-$1.23—
Earlier years, FY 2010 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 6, 2026050501
10-QAug 6, 2026036424
10-QMay 11, 2026022276
10-KMar 13, 2026010102
10-QNov 7, 2025021287
10-QAug 13, 2025011910
10-QMay 7, 2025009044
10-KMar 12, 2025010051
10-QNov 12, 2024044841
10-QAug 13, 2024031639

Provenance

ProvenanceData status and checks

Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR